XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 12 - Segment Data - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues [1] $ 58,170 $ 50,645    
Sterilization and Disinfection Control (b) 37,249 31,183    
Operating expense 31,669 31,847    
Operating income (loss) 5,580 (664)    
Nonoperating expense, net (1,675) (273)    
Sterilization and Disinfection Control [Member]        
Revenues     $ 58,170  
Clinical Genomics [Member]        
Revenues [2]       $ 50,645
Operating Segments [Member]        
Operating expense 31,669 31,847    
Operating income (loss) 5,580 (664)    
Nonoperating expense, net 1,675 273    
Earnings (loss) before income taxes 3,905 (937)    
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Revenues [1],[3] 22,957 [4] 15,927    
Sterilization and Disinfection Control (b) [3] 15,558 11,591    
Operating Segments [Member] | Clinical Genomics [Member]        
Revenues [1] 11,404 13,369    
Sterilization and Disinfection Control (b) 6,490 6,728    
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Revenues [1] 12,008 9,889    
Sterilization and Disinfection Control (b) 7,959 6,433    
Operating Segments [Member] | Calibration Solutions [Member]        
Revenues [1] 11,801 11,460    
Sterilization and Disinfection Control (b) $ 7,242 $ 6,431    
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021.
[3] Includes post-acquisition GKE results during the three months ended June 30, 2024.
[4] Revenues of $6,254 from GKE are included in the Sterilization and Disinfection Control division during the three months ended June 30, 2024.